Potentially curative treatment in patients with hepatocellular cancer--results from the liver cancer research network
| Autor: | A. Zeringue, J. Li, Timothy R. Morgan, Lewis R. Roberts, Nezam H. Afdhal, Smruti R. Mohanty, A. Di'Bisceglie, R. S. Chari, Jorge A. Marrero, Jonathan M. Schwartz, Fasiha Kanwal, D. Vanthiel, Alex S. Befeler, J. Kahn |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male medicine.medical_specialty Cirrhosis Databases Factual medicine.medical_treatment Liver transplantation Gastroenterology Internal medicine Medicine Humans Pharmacology (medical) Stage (cooking) neoplasms Aged Aged 80 and over Hepatology Performance status business.industry Hazard ratio Liver Neoplasms Middle Aged Plastic Surgery Procedures medicine.disease Prognosis Survival Analysis digestive system diseases United States Liver Transplantation Treatment Outcome Otorhinolaryngology Catheter Ablation Female business Liver cancer Biomedical sciences |
| Zdroj: | Alimentary pharmacologytherapeutics. 36(3) |
| ISSN: | 1365-2036 |
| Popis: | SUMMARY Background The extent to which potentially curative therapies are used in patients with hepatocellular cancer (HCC) and their related outcomes are unknown in the US. Aim To determine the rate and outcomes of potentially curative treatment in patients with HCC. Methods Eleven US centers followed patients with HCC between 2001 and 2007. We determined rates of liver transplantation, surgical resection, or tumour ablation during follow-up, examined differences in adjusted survival of patients receiving these treatments, and determined the factors associated with receipt of potentially curative treatment. Results Of the 267 patients, 76 (28%) patients had early HCC, defined as Child A or B cirrhosis, with a solitary HCC or ≤3 nodules, each ≤3 cm. Of these, 53 (69.7%) received curative treatment. Thirty six percent of patients with non-early HCC received curative treatment. Compared to patients with non-early HCC who did not receive curative treatment, patients with early HCC and curative treatment had the best survival [hazard ratio, HR = 0.19 (95% CI, 0.08–0.42)] followed by patients with advanced HCC who received curative treatment [HR = 0.37 (95% CI, 0.22–0.64)]. Baseline performance status was significantly associated with receipt of curative treatment as well as survival after adjusting for demographics, clinical characteristics, and HCC stage. Conclusions In this multicenter database, most of the patients with early HCC received potentially curative treatment. However, only 28% of patients had early HCC. One-third of patients with non-early HCC also underwent curative therapy. Potentially curative treatment improved survival and this effect was seen in patients with early as well as non-early HCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text